title: [Application of imiquimod and resiquimod in dermatology].
abstract: Imiquimod (R-837) and Resiquimod (R-838), two novel small-molecular-weight immune response modifiers, have similar structure. They have anti-virus and anti-tumor activities and can be used as B lymphocyte activators and adjuvants. They are widely used in dermatology to treat virus dermatoses and cutaneous benign or malignant tumors.
authors.affiliation: Department of Dermatology, PUMC Hospital, CAMS and PUMC, Beijing 100730, China. axukejian@tom.com
authors.forename: Ke-Jian
authors.initials: KJ
authors.lastname: Xu
authors.forename: Yue-Hua
authors.initials: YH
authors.lastname: Liu
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000634:Aminoquinolines / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003218:Condylomata Acuminata / Q000188:drug therapy*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D000077271:Imiquimod; D012878:Skin Neoplasms / Q000188:drug therapy*
chemical_list: D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D000970:Antineoplastic Agents; D007093:Imidazoles; D000077271:Imiquimod; C402365:resiquimod